Alhemo®▼ (concizumab)

Patient Alert Card

Carry this card with you at all times and show it to any healthcare professional involved in your treatment.

For more information, please refer to the Package Leaflet

Information for healthcare professionals reading this card:

This patient is being treated with Alhemo® (concizumab) which is indicated for routine prophylaxis of bleeding in patients of 12 years of age or more with:

- haemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors
- haemophilia B (congenital factor IX deficiency) with or without FIX inhibitors

Risk of thromboembolic events

Cases of arterial and venous non-fatal thromboembolic events (i.e., blood clots) have been reported in the concizumab clinical trials.

In case of an emergency:

- Contact a doctor for immediate medical care.
- Should any questions related to your haemophilia A/B or current treatment arise, please have them contact your doctor.

Contact information for treating haematologist:

Name: _____

Contact details: _____

▼ This medicinal product is subject to additional monitoring. If you get any side effects, talk to your doctor, pharmacist or nurse. Side effects can be reported directly to the Health Products Regulatory Authority (HPRA) Pharmacovigilance, website: www.hpra.ie. And to the Novo Nordisk Medical Department at complaintireland@novonordisk.com or Tel: 01 8629700.